3Q EARNINGS: Harvoni to the rescue as Gilead's Sovaldi sales dip
This article was originally published in Scrip
Executive Summary
Gilead Sciences fell 4.3% to $108.61 in after-hours trading on 28 October following the company's third quarter earnings report, which showed a larger than expected drop in Sovaldi (sofosbuvir) sales as doctors delayed hepatitis C treatments in anticipation of Gilead's Harvoni (sofosbuvir/ledipasvir) launch.